Bifidobacterium breve Yakult

Bifidobacterium breve Yakult is a proprietary probiotic strain that produces bacteriocins and short-chain fatty acids to modulate gut microbiota composition. This strain specifically supports skin barrier function through the gut-skin axis and reduces toxic phenol compound accumulation.

Origin & History

Bifidobacterium breve strain Yakult (BbrY) is a specific probiotic strain isolated and developed by Yakult Honsha Co., Ltd. from the naturally occurring B. breve bacteria found in the human gut microbiota. This strain is cultured in fermented milk products and characterized by its ability to survive and proliferate in the gastrointestinal tract, reaching viable counts exceeding 10⁹ CFU/g in fecal samples following oral administration.

Historical & Cultural Context

The search results do not provide information regarding historical or traditional use of Bifidobacterium breve. This strain represents a modern, scientifically developed probiotic rather than a traditional botanical or herbal ingredient with documented historical use.

Health Benefits

• May support skin hydration and barrier function - one RCT showed prevention of hydration level decreases in the stratum corneum (Moderate evidence, PMID: 4034291)
• Reduces serum and urine phenol levels - clinical trial demonstrated decreased phenol metabolism over 4 weeks (Moderate evidence, PMID: 4034291)
• May improve gastrointestinal symptoms when combined with other probiotics - one study found symptom improvement with decreased hydrogen production (Preliminary evidence, PMID: 22402407)
• Demonstrated colonization ability - human feeding experiments confirmed survival through GI tract with fecal recovery exceeding 10⁹ CFU/g (Strong evidence)
• Failed to maintain ulcerative colitis remission - large RCT (n=195) showed no benefit vs placebo for UC maintenance (Strong negative evidence, PMID: 29450747)

How It Works

Bifidobacterium breve Yakult colonizes the intestinal tract and produces butyrate, acetate, and propionate, which strengthen intestinal barrier integrity. The strain metabolizes phenolic compounds through phenol hydroxylase enzymes, reducing systemic phenol absorption. Through the gut-skin axis, improved intestinal permeability and reduced inflammatory cytokines enhance stratum corneum hydration and barrier function.

Scientific Research

The B-FLORA trial (PMID: 29450747, 19616336), a double-blind RCT with 195 Japanese UC patients, found no significant effect on maintaining relapse-free survival over 48 weeks, leading to early discontinuation. However, a skin hydration RCT (PMID: 4034291) in healthy females demonstrated positive effects on skin barrier function and phenol metabolism. Earlier research suggested potential benefits for UC when combined with galacto-oligosaccharide as a synbiotic.

Clinical Summary

One randomized controlled trial demonstrated that Bifidobacterium breve Yakult prevented decreases in stratum corneum hydration levels, showing moderate evidence for skin barrier support. A clinical trial over 4 weeks showed significant reductions in both serum and urine phenol levels, indicating effective phenol detoxification. However, research is limited with small sample sizes and relatively short study durations. More large-scale, long-term trials are needed to establish definitive clinical benefits.

Nutritional Profile

Bifidobacterium breve Yakult is a probiotic microorganism, not a conventional food ingredient, so macronutrient and micronutrient content is not applicable in traditional dietary terms. The preparation typically delivers live bacterial cells measured in colony-forming units (CFU); commercial Yakult formulations contain approximately 6.5 billion CFU (6.5 × 10⁹) of B. breve Yakult per 65ml serving, though specific B. breve Yakult strains are also delivered in capsule or powder formats at varying CFU counts (typically 10⁹ to 10¹⁰ CFU per dose in research settings). The bioactive components of functional relevance include: (1) cell wall constituents such as lipoteichoic acids and peptidoglycans, which interact with host toll-like receptors (TLR-2, TLR-4) to modulate immune signaling; (2) exopolysaccharides (EPS) produced by the strain, which contribute to gut mucosa adhesion and immunomodulatory effects; (3) short-chain fatty acids (SCFAs) — primarily acetate — generated as fermentation metabolites in the colon, with acetate being the predominant SCFA produced by Bifidobacterium species generally; (4) B-group vitamins, particularly folate (B9) and riboflavin (B2), which Bifidobacterium species are known to biosynthesize in situ in the gut, though quantities are strain- and substrate-dependent and not precisely quantified for this specific strain; (5) conjugated linoleic acid (CLA) precursor activity has been noted in some Bifidobacterium strains but is not confirmed at specific concentrations for B. breve Yakult. Bioavailability context: as a live organism, the 'nutrient delivery' is indirect — benefits arise from colonization, fermentation activity, and host-microbe signaling rather than direct nutrient absorption. Survival through gastric acid is strain-dependent; B. breve Yakult has demonstrated gastric acid and bile salt tolerance in vitro, supporting sufficient viable cell delivery to the colon. The bacterial cells themselves contribute negligible macronutrient load (protein, fat, carbohydrate) at typical dosing concentrations.

Preparation & Dosage

Clinically studied dosage: 10 billion CFU of B. breve strain Yakult per daily pack (100 mL fermented milk), often combined with 1 billion CFU L. acidophilus, administered for 4-48 weeks. Powder formulation with galacto-oligosaccharide has been used for up to 1 year. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lactobacillus acidophilus, galacto-oligosaccharide (GOS), Lactobacillus casei Shirota, soy protein

Safety & Interactions

Bifidobacterium breve Yakult is generally well-tolerated with minimal reported adverse effects in healthy individuals. Mild gastrointestinal symptoms like bloating or gas may occur during initial supplementation. Immunocompromised patients should consult healthcare providers before use due to theoretical risk of bacteremia. Safety during pregnancy and lactation has not been established, requiring medical supervision for use in these populations.